Santhera Pharmaceuticals Holding AG Logo

Santhera Pharmaceuticals Holding AG

Develops innovative medicines for rare neuromuscular and mitochondrial disorders.

SANN | SW

Overview

Corporate Details

ISIN(s):
CH1276028821
LEI:
54930035HAOFTTQH0U85
Country:
Switzerland
Address:
HOHENRAINSTRASSE 24, 4133 PRATTELN
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Santhera Pharmaceuticals Holding AG is a specialty pharmaceutical company focused on the development and commercialization of innovative medicines for patients with rare diseases. The company targets conditions with high unmet medical needs, primarily in the area of rare neuromuscular and mitochondrial disorders. Santhera's mission is to provide treatment options for diseases that severely impact the lives of affected children and adults and currently have limited or no available therapies. Its development efforts include advanced treatments such as gene therapy for conditions like LAMA2-deficient congenital muscular dystrophy (CMD).

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Santhera Pharmaceuticals Holding AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Santhera Pharmaceuticals Holding AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Santhera Pharmaceuticals Holding AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2022-01-11 N/A Non-Executive member Buy None 42,600.00 CHF
2022-01-10 N/A Executive member Buy None 14,420.00 CHF
2022-01-05 N/A Executive member Buy None 37,000.00 CHF

Peer Companies

AIM ImmunoTech Inc. Logo
Develops immuno-therapeutics for cancers, immune disorders, and viral diseases.
United States of America
AIM
AKANDA CORP. Logo
Cultivates and distributes pharma-quality medical cannabis for patients in legal markets worldwide.
United States of America
AKAN
Akari Therapeutics Plc Logo
A clinical-stage oncology company developing next-gen ADCs for targeted cancer therapy.
United States of America
AKTX
Akebia Therapeutics, Inc. Logo
Developing and commercializing novel, FDA-approved therapeutics for kidney disease.
United States of America
AKBA
Akero Therapeutics, Inc. Logo
A clinical-stage biotech developing therapies for serious metabolic diseases like MASH.
United States of America
AKRO
Alaunos Therapeutics, Inc. Logo
Developing TCR-T cell therapies to treat solid tumors by targeting specific cancer mutations.
United States of America
TCRT
Aldeyra Therapeutics, Inc. Logo
Biotech developing therapies for ocular and systemic immune-mediated inflammation.
United States of America
ALDX
Alector, Inc. Logo
Pioneers immuno-neurology therapies for neurodegenerative diseases like Alzheimer's.
United States of America
ALEC
Aligos Therapeutics, Inc. Logo
Clinical-stage biopharma developing novel oral therapies for liver and viral diseases.
United States of America
ALGS
ALK-Abelló Logo
Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.
Denmark
ALK

Talk to a Data Expert

Have a question? We'll get back to you promptly.